AR075604A1 - Anticuerpos contra un ligando que induce proliferacion (april) - Google Patents

Anticuerpos contra un ligando que induce proliferacion (april)

Info

Publication number
AR075604A1
AR075604A1 ARP100100546A ARP100100546A AR075604A1 AR 075604 A1 AR075604 A1 AR 075604A1 AR P100100546 A ARP100100546 A AR P100100546A AR P100100546 A ARP100100546 A AR P100100546A AR 075604 A1 AR075604 A1 AR 075604A1
Authority
AR
Argentina
Prior art keywords
april
link
antibody
antibodies against
induces proliferation
Prior art date
Application number
ARP100100546A
Other languages
English (en)
Inventor
Fiona Clare Kimberley
Uyen Truong Phan
Jan Paul Medema
Eenennaam Hans Van
Marco Guadagnoli
Original Assignee
Organon Nv
Stichting Top Inst Pharma
Vrije Universiteit Medisch Ct
Univ Groningen
Amc Amsterdam
Groningen Acad Ziekenhuis
Pepscan Holding N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42289631&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR075604(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Organon Nv, Stichting Top Inst Pharma, Vrije Universiteit Medisch Ct, Univ Groningen, Amc Amsterdam, Groningen Acad Ziekenhuis, Pepscan Holding N V filed Critical Organon Nv
Publication of AR075604A1 publication Critical patent/AR075604A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proveen además composiciones de anticuerpos específicos anti-APRIL, y métodos para usar tales anticuerpos en la modulacion de la actividad biologica de APRIL, particularmente en enfermedades inflamatorias, inhibicion de la proliferacion celular y cáncer. Reivindicacion 1: Un compuesto ligante que se liga a APRIL humano caracterizado porque comprende: a) una region variable de la cadena pesada de un anticuerpo que comprende por lo menos una CDR seleccionada entre el grupo que consiste en las SEQ ID Nss: 9, 10, 11, 15, 16 y 17, o una variante de cualquiera de dichas secuencias; y/o b) una region variable de la cadena liviana de un anticuerpo que comprende por lo menos una CDR seleccionada entre el grupo que consiste en las SEQ ID Nss: 12, 13, 14, 18, 19 y 20, o una variante de cualquiera de dichas secuencias.
ARP100100546A 2009-03-02 2010-02-25 Anticuerpos contra un ligando que induce proliferacion (april) AR075604A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09154079 2009-03-02
EP09157722 2009-04-09

Publications (1)

Publication Number Publication Date
AR075604A1 true AR075604A1 (es) 2011-04-20

Family

ID=42289631

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100546A AR075604A1 (es) 2009-03-02 2010-02-25 Anticuerpos contra un ligando que induce proliferacion (april)

Country Status (16)

Country Link
US (4) US8895705B2 (es)
EP (3) EP3103476B1 (es)
JP (3) JP5867706B2 (es)
AR (1) AR075604A1 (es)
AU (1) AU2010220421B9 (es)
CA (2) CA2919467C (es)
CY (1) CY1117942T1 (es)
DK (2) DK2403528T3 (es)
ES (2) ES2573404T3 (es)
HR (1) HRP20160702T1 (es)
HU (1) HUE027826T2 (es)
PL (1) PL2403528T3 (es)
PT (1) PT2403528E (es)
SI (1) SI2403528T1 (es)
SM (1) SMT201600239B (es)
WO (1) WO2010100056A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010100056A2 (en) 2009-03-02 2010-09-10 Stichting Top Institute Pharma Antibodies against a proliferating inducing ligand (april)
CA2875451A1 (en) 2012-06-08 2013-12-12 Kinki University Antibody against transporter and use thereof
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
CA2938152A1 (en) * 2014-02-10 2015-08-13 Merck Sharp & Dohme Corp. Antibodies that bind to human tau and assay for quantifying human tau using the antibodies
EP3107582A4 (en) * 2014-02-19 2018-02-14 Emergent BioSolutions Canada Inc. Ebola monoclonal antibodies
EP3116544A4 (en) 2014-03-11 2017-08-23 The Board of Trustees of the Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
EP3245230B1 (en) 2015-01-15 2020-12-16 Université Grenoble Alpes Anti april (a proliferation-inducing ligand) antibodies and their uses for the prognosis and/or diagnosis of cancer
JO3746B1 (ar) 2015-03-10 2021-01-31 Aduro Biotech Inc تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
MY197345A (en) * 2015-11-25 2023-06-14 Visterra Inc Antibody molecules to april and uses thereof
RU2729116C2 (ru) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
CA3053305A1 (en) 2017-02-17 2018-08-23 Mapp Biopharmaceutical, Inc. Monoclonal antibodies and cocktails for treatment of ebola infections
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
KR20200058411A (ko) 2017-08-30 2020-05-27 베이징 슈안이 파마사이언시스 컴퍼니, 리미티드 인터페론 유전자 조절인자의 자극제로서의 환식 다이-뉴클레오타이드
KR20200087143A (ko) 2017-10-10 2020-07-20 그릿스톤 온콜로지, 인코포레이티드 핫스팟을 이용한 신생항원 동정
JP2021503897A (ja) 2017-11-22 2021-02-15 グリットストーン オンコロジー インコーポレイテッド 新生抗原のためのジャンクションエピトープ提示の低減
WO2020144535A1 (en) 2019-01-08 2020-07-16 Aduro Biotech Holdings, Europe B.V. Methods and compositions for treatment of multiple myeloma
WO2021243298A1 (en) * 2020-05-29 2021-12-02 Chinook Therapeutics, Inc. Methods of treating iga nephropathy with an april binding antibody
TW202400637A (zh) 2022-04-25 2024-01-01 美商威特拉公司 April之抗體分子及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946A (en) 1847-01-26 Improvement in carriage-wheels
US778A (en) 1838-06-12 Thomas wright
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
WO1996014328A1 (en) 1994-11-07 1996-05-17 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US6171787B1 (en) 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease
WO1999012965A2 (en) 1997-09-12 1999-03-18 Biogen, Inc. April- a novel protein with growth effects
DE60028830T2 (de) 2000-02-16 2007-01-18 Genentech, Inc., South San Francisco Anti-april antikörper und hybridomazellen
CA2408617A1 (en) * 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
EP1294949A4 (en) 2000-06-15 2004-08-25 Human Genome Sciences Inc HUMAN TUMORNESCROSE FACTOR DELTA AND EPSILON
EP1401870A4 (en) 2001-05-24 2006-04-19 Human Genome Sciences ANTIBODIES AGAINST TUMOR NECROSIS FACTOR DELTA (APRIL)
EA007984B1 (ru) * 2001-08-03 2007-02-27 Дженентек, Инк. ПОЛИПЕПТИДЫ TACIs И BR3 И ИХ ПРИМЕНЕНИЕ
AU2003226356A1 (en) 2002-04-12 2003-10-27 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
CA2554526A1 (en) * 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
WO2005120571A2 (en) 2004-06-07 2005-12-22 Ramot At Tel Aviv University Ltd. Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation
CA2569190A1 (en) 2004-07-15 2006-01-19 Technische Universitaet Wien Method for the detection of fusarium graminearum
WO2010100056A2 (en) 2009-03-02 2010-09-10 Stichting Top Institute Pharma Antibodies against a proliferating inducing ligand (april)

Also Published As

Publication number Publication date
EP2403528B1 (en) 2016-04-20
EP3103476A2 (en) 2016-12-14
AU2010220421A8 (en) 2015-01-29
JP5867706B2 (ja) 2016-02-24
CA2754127A1 (en) 2010-09-10
PL2403528T3 (pl) 2017-08-31
DK3103476T3 (da) 2022-10-17
HRP20160702T1 (hr) 2016-07-29
SMT201600239B (it) 2016-08-31
JP2012519198A (ja) 2012-08-23
AU2010220421B9 (en) 2015-03-05
AU2010220421B2 (en) 2015-01-22
ES2928709T3 (es) 2022-11-22
PT2403528E (pt) 2016-06-08
AU2010220421A1 (en) 2011-09-15
EP2403528A2 (en) 2012-01-11
CA2919467C (en) 2018-04-17
ES2573404T3 (es) 2016-06-07
US8895705B2 (en) 2014-11-25
HUE027826T2 (en) 2016-11-28
SI2403528T1 (sl) 2016-07-29
US20120195909A1 (en) 2012-08-02
EP3103476A3 (en) 2017-03-01
CA2754127C (en) 2017-04-18
AU2010220421B8 (en) 2015-01-29
US20130295103A1 (en) 2013-11-07
US9000128B2 (en) 2015-04-07
JP2015172073A (ja) 2015-10-01
CA2919467A1 (en) 2010-09-10
US20130302353A1 (en) 2013-11-14
EP3103476B1 (en) 2022-07-27
CY1117942T1 (el) 2017-05-17
WO2010100056A2 (en) 2010-09-10
JP2015164956A (ja) 2015-09-17
DK2403528T3 (en) 2016-05-23
WO2010100056A3 (en) 2010-11-18
EP4147719A1 (en) 2023-03-15
US20130273064A1 (en) 2013-10-17

Similar Documents

Publication Publication Date Title
AR075604A1 (es) Anticuerpos contra un ligando que induce proliferacion (april)
AR122771A2 (es) Anticuerpos para el tratamiento del cáncer, conjugado, composición farmacéutica, ácido nucleico y célula huésped
TW200716667A (en) Binding agents
MY174493A (en) Binding agents
MY166776A (en) Humanised anti-ctla4 antibodies
AR077756A1 (es) Anticuerpos especificos para bacterias gram-positivas
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
HN2005029978A (es) Formulaciones
AR096895A2 (es) Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp)
AR083747A1 (es) Anticuerpos anti-il-23
CU23978B1 (es) Composiciones para anticuerpos que se dirigen a la proteína de complemento c5
ATE475672T1 (de) Anti-il-23-antikörper
BR112015014751A2 (pt) anticorpos anti-tau humanos
PE20080035A1 (es) Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
EA201390453A1 (ru) Человеческие анти-тау антитела
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
TR201910348T4 (tr) Matriks metalloproteinaz 9 için antikorlar.
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
AR062268A1 (es) Agentes ligantes direccionados dirigidos a pdgfr-alfa y sus usos
EA201491575A1 (ru) Антитела к матриксной металлопротеиназе 9
AR080740A1 (es) Anticuerpos anti- cxcr4 humanizados para el tratamiento de cancer
CO6362025A2 (es) Anticuerpos contra la proteína tweak humana y usos de los mismos
WO2011116212A3 (en) Bone morphogenetic protein receptor binding agents and methods of their use

Legal Events

Date Code Title Description
FA Abandonment or withdrawal